Low Recruitment in a Double-Blind, Placebo-Controlled Trial of Ocrelizumab for Autoimmune Encephalitis: A Case Series and Review of Lessons Learned

INTRODUCTION: Observational data suggest that B-cell-depleting therapies are effective for antibody-mediated autoimmune encephalitis. However, randomized controlled trials are needed. Here, we report challenges encountered in a randomized, placebo-controlled trial of ocrelizumab for autoimmune encep...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackburn, Kyle M., Denney, David A., Hopkins, Steven C., Vernino, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095811/
https://www.ncbi.nlm.nih.gov/pubmed/35129803
http://dx.doi.org/10.1007/s40120-022-00327-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095811/
https://www.ncbi.nlm.nih.gov/pubmed/35129803
http://dx.doi.org/10.1007/s40120-022-00327-x

Ejemplares similares